Spot On CML Grows in the Philippines

Spot On CML Grows in the Philippines

In 2017, The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) embarked on a groundbreaking collaboration to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries.

The collaboration is called Spot On CML and utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.

Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

The patients, the treating physicians at Philippine General, and the team at The Max Foundation all offer their heartfelt gratitude to Fred Hutch for this wonderful collaboration.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….

  • The Max Foundation and Cepheid expand collaboration to increase access to diagnostics

    The Max Foundation and Cepheid expand collaboration to increase access to diagnostics

    The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).

  • First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….